Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12797755 | 0.76 | CYP1A2 (0.43) | CYP1A2KDM4EHPGDSMN1; SMN2MEN1 | |
| SCHEMBL16716677 | 0.73 | CYP1A2 (0.41) | CYP1A2KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL10132581 | 0.70 | KDM4E (0.44) | CYP1A2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL23571430 | 0.70 | CYP1A2 (0.39) | CYP1A2KDM4EMEN1KMT2AHTT | |
| SCHEMBL2362490 | 0.69 | CYP1A2 (0.41) | CYP1A2KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL2362492 | 0.69 | CYP1A2 (0.41) | CYP1A2KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL13754004 | 0.68 | MAPT (0.44) | CYP1A2KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL14864590 | 0.68 | CYP1A2 (0.55) | CYP1A2KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL2680148 | 0.68 | CYP1A2 (0.47) | CYP1A2KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL7801386 | 0.64 | KDM4E (0.49) | CYP1A2KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20110263486-A1 | Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation | 4SC AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | disclosed |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-7601745-B2 | Heterocyclic NF-kB inhibitors | 4SC AG (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20090176716-A1 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION | LEBAN JOHANN | 2009-07-09 | — | — | US | disclosed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176716-A1 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | CYP1A2 2691/4885KDM4E 1469/4885HSD17B10 507/4885 |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, IKBKB, NFKB2 | CYP1A2 2174/4885KDM4E 1503/4885HSD17B10 1606/4885 |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, NFKB2, NFRKB | CYP1A2 3847/4885KDM4E 3102/4885HSD17B10 785/4885 |
| US-20110263486-A1 | Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | CYP1A2 2641/4885KDM4E 1401/4885HSD17B10 519/4885 |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | CYP1A2 2166/4885KDM4E 1244/4885HSD17B10 1169/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | CYP1A2 3922/4885KDM4E 2640/4885HSD17B10 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.